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A B S T R A C T
Antimicrobial resistance in Streptococcus suis, a global zoonotic pathogen of pigs, has been mostly studied only in
diseased animals using surveys that have not evaluated changes over time.
We compared patterns of resistance between S. suis isolates from clinical cases of disease (CC) and non-
clinical case (NCC) pigs in England, collected over two discrete periods, 2009–2011 and 2013–2014. Minimum
inhibitory concentrations (MIC) of 17 antimicrobials (nine classes) were determined on 405 S. suis isolates
categorised by sampling period and disease association to assess changes in resistance over time and association
with disease. First, isolates were characterized as resistant or susceptible using published clinical breakpoints.
Second, epidemiological cut-oﬀs (ECOFF) were derived from MIC values, and isolates classiﬁed as wild type
(WT) below the ECOFF and non-wild type (NWT) above the ECOFF. Finally, isolate subsets were analysed for
shifts in MIC distribution.
NCC isolates were more resistant than CC isolates to cephalosporins, penams, pleuromutilins, potentiated
sulphonamides and tetracyclines in both study periods. Resistance levels among CC isolates increased in
2013–2014 relative to 2009–2011 for antimicrobials including aminoglycosides, cephalosporins, ﬂuor-
oquinolones, pleuromutilins, potentiated sulphonamides and tetracyclines. The prevalence of isolates cate-
gorised as NWT for ﬁve or more classes of antimicrobials was greater among NCC than CC isolates for both time
periods, and increased with time. This study used standardised methods to identify signiﬁcant shifts in anti-
microbial resistance phenotypes of S. suis isolated from pigs in England, not only over time but also between
isolates from known clinical cases or disease-free pigs.
1. Introduction
Streptococcus suis (S. suis) is a global pig pathogen which has a major
impact on productivity, antimicrobial use and pig welfare (Gottschalk,
2012). Human disease due to S. suis was ﬁrst described in Europe in the
1950s (Wertheim et al., 2009). In Great Britain, S. suis is one of the most
common causes of systemic disease in post-weaned pigs to be reported
by diagnostic laboratories in recent years, resulting in septicemia,
meningitis, pneumonia and arthritis.
There is marked and large diversity among S. suis strains, with 33
serotypes based on capsular polysaccharides (Gottschalk, 2012), and
many non-serotypable strains exist, but most clinical cases are caused
by a small number of serotypes. Disease associated strains are char-
acterized by an ensembles of a diverse group of virulence related genes,
which may vary geographically, and other genomic features but other
strains with apparently low pathogenic potential can be isolated widely
http://dx.doi.org/10.1016/j.vetmic.2017.06.002
Received 28 September 2016; Received in revised form 1 June 2017; Accepted 3 June 2017
⁎ Corresponding author.
E-mail addresses: jh937@cam.ac.uk (J. Hernandez-Garcia), jw401@cam.ac.uk (J. Wang), or226@cam.ac.uk (O. Restif), mah1@cam.ac.uk (M.A. Holmes),
am2382@cam.ac.uk (A.E. Mather), lucy.weinert@gmail.com (L.A. Weinert), tmw37@cam.ac.uk (T.M. Wileman), Jill.thomson@sac.co.uk (J.R. Thomson),
p.langford@imperial.ac.uk (P.R. Langford), brendan.wren@lshtm.ac.uk (B.W. Wren), ARycroft@rvc.ac.uk (A. Rycroft), djm47@cam.ac.uk (D.J. Maskell),
awt1000@cam.ac.uk (A.W. Tucker).
Veterinary Microbiology 207 (2017) 117–124
0378-1135/ © 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/BY/4.0/).
MARK
as part of the microbiota in the respiratory tract and tonsils of pigs
without streptococcal disease (Weinert et al., 2015).
Over the past decade, an increasing level of antimicrobial resistance
has been noted in food-borne and other pathogens (Palmieri et al.,
2011). This has been recognized as a global problem for public health
and the worldwide emergence of multidrug-resistant phenotypes is
causing increasing concern (O'Neill, 2016). Antimicrobial resistance
proﬁles, and genetic determinants regulating resistance mechanisms,
have been studied in isolates of S. suis from pigs and, to a lesser extent,
from human cases (Palmieri et al., 2011). Penicillin resistance in S. suis
was ﬁrst reported in the UK from a serotype 2 isolate from a human in
1980 (Shneerson et al., 1980) and has emerged in S. suis isolates from
pigs worldwide (Zhang et al., 2008; Callens et al., 2013). More recently,
resistance to third-generation cephalosporins was reported in China and
Europe (Hu et al., 2011; Zhang et al., 2015; van Hout et al., 2016).
Extensive resistance has been reported against aminoglycosides
(Holden et al., 2009; Hu et al., 2011; Palmieri et al., 2011), β-lactams,
trimethoprim and amphenicols (Wisselink et al., 2006; Holden et al.,
2009; Hu et al., 2011; Ge et al., 2012).
Resistance mechanisms in S. suis include new gene acquisition and
gene expression modiﬁcations, as described for tetracyclines, macro-
lides, lincomycin, streptogramin B (Palmieri et al., 2011; Chen et al.,
2013) and ﬂuoroquinolones (Escudero et al., 2011). Other mechanisms
based on gene mutations have been described for tiamulin, quinolones
and penicillin (Martel et al., 2001; Gurung et al., 2015). However, other
reasons underlying ineﬀective responses to antimicrobial treatment of
S. suis disease might include bioﬁlm formation and the production of
persistent cells (Seitz et al., 2016). Although reports from diﬀerent parts
of the world indicate widespread clinical resistance in S. suis to diverse
antimicrobials (Aarestrup et al., 1998; Callens et al., 2013; Varela et al.,
2013; de Jong et al., 2014; Zhang et al., 2015; van Hout et al., 2016),
there have been no systematic comparisons of antimicrobial suscept-
ibility for S. suis isolates collected from pig populations in the same
geographic area at diﬀerent time points using standardised metho-
dology.
Current eﬀorts to improve provision of surveillance data to allow
monitoring and international comparisons of antimicrobial resistance
for S. suis are hampered by diﬀerences in testing methodologies and
interpretation criteria that are subjective. Standardized methods and
cut-oﬀs have been proposed by the Clinical and Laboratorial Standards
Institute (CLSI) and the European Committee on Antimicrobial
Susceptibility Testing (EUCAST), but the need remains for better har-
monization and normalization of results (Kronvall, 2010; Kahlmeter,
2015). Furthermore, clinical breakpoints are not deﬁned for most of the
antimicrobials; the literature reports of antimicrobial resistance in S.
suis apply diﬀerent clinical breakpoints, which further complicates
comparisons of results from diﬀerent studies. Given these limitations,
antimicrobial resistance phenotypes for bacteria have also been studied
by determining minimum inhibitory concentration (MIC) values and by
categorizing isolates according to epidemiological cut-oﬀ (ECOFF) va-
lues for each antimicrobial.
This study describes the comparative phenotypic antimicrobial re-
sistance characteristics of 405 isolates of S. suis from commercial
slaughter pigs in England, representing carefully catalogued isolates of
known disease-associated or non-disease associated provenance, from
two time periods (2009–2011 and 2013–2014).
2. Materials and methods
2.1. Sample collection
A total of 405 isolates of S. suis were obtained covering two periods
2009–2011 and 2013–2014. These were further split into two classes:
disease associated clinical cases (CC) and non-disease associated non-
clinical cases (NCC). Disease-associated CC isolates from both
2009–2011 (N = 93, from 83 diﬀerent laboratory submissions) and
2013–2014 (N = 117, from 113 diﬀerent laboratory submissions) were
cultured from lung, meninges, or other systemic sites of pigs between
weaning and slaughter age (1–5 months) with clinical signs and/or
gross pathology consistent with S. suis infection (including meningitis,
septicaemia, arthritis, pneumonia) submitted from pig farms from dif-
ferent geographic locations in England to Animal and Plant Health
Agency (APHA) veterinary investigation centres (VICs).
Non-disease associated NCC isolates from 2009 to 2011 (N = 66
from 44 diﬀerent laboratory submissions) were cultured from tonsils or
tracheobronchial swabs of pigs between weaning and slaughter age
from diﬀerent geographic locations in England submitted to the APHA
VICS for post-mortem examination in which S. suis disease was not
diagnosed. None of the clinical histories of these cases reported strep-
tococcal disease at the time of submission. NCC isolates from 2013 to
2014 (N = 129 from 113 pigs) originated from nine breeding sources in
the East of England which reported no S. suis related clinical signs at the
time; these isolates were obtained from 250 tonsils scrapes, 125 from 5
week old pigs and 125 from 20 week old pigs, and submitted to the
Scottish Agricultural College (SAC) veterinary laboratories for isolation
of S. suis. Antimicrobial treatments prior to sample collection were not
considered in this study.
The NCC isolates from 2009 to 2011 were isolated by inoculating
the samples from pigs onto Columbia agar containing 5% (v/v) sheep
blood (TCS biosciences Ltd., Bucks, UK) and incubating at 37 °C in
aerobic conditions for up to 48 h. Up to three suspect S. suis colonies
were selected from each plate based on α-haemolysis and colony
morphology, then sub-cultured and tested in pure culture with a bio-
chemical proﬁling kit (API 32-Strep, Bio-Mérieux, Mercy-l’Étoile,
France).
For the NCC samples collected in 2013–2014, three colonies were
selected per inoculated plate; API biochemical proﬁle was done and S.
suis colonies from the same plate presenting the same biochemical
proﬁle were considered the same strain so just one of them was selected
for the ﬁnal collection and stored at −80 °C until testing. NCC isolates
collected in 2013–2014 were epidemiologically related as they came
from the same production pyramid, some of them came from the same
farm, and some tonsillar scrapes yielded more than one isolate, which
reduces this collection representativeness. In contrast, most of the NCC
samples collected in 2009–2011, and the CC samples in both periods,
represented cases submitted from pig producers located in diﬀerent
geographic areas in England.
2.2. Antimicrobial susceptibility testing
MIC were determined using the micro-broth dilution method, at
Quotient Bioresearch, Fordham, UK in accordance the CLSI Approved
standard M100-S25 (2015), VET01-A4 (2013b) and VET01-S2 (2013a)
as recently described (de Jong et al., 2014; van Hout et al., 2016).
Seventeen diﬀerent antimicrobial compounds, representing nine anti-
microbial classes, were tested across a range of two-fold step dilutions
(Table 1). Quality controls were included according to CLSI re-
commendations VET01-A4 (2013b) and VET01-S2 (2013a); reference
strains of Enterococcus fecalis (ATCC 29212), Staphylococcus aureus
(ATCC 29213), and Streptococcus pneumoniae (ATCC 49619) were used
for this purpose.
2.3. Data analysis
MIC distributions for CC and NCC isolates were analysed separately
for 2009–2011 and 2013–2014, using the following methods.
2.3.1. MIC value distribution and epidemiological cut-oﬀ values (ECOFF)
MIC distributions were evaluated for the presence of one or more
clusters. Distributions were classed as unimodal where MIC values were
spread surrounding a central value, or median, in one “bell-shaped”
cluster and multimodal when two or more clusters represented multiple
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phenotypic groups.
The ECOFF values were deﬁned as the highest MIC value of the
wild-type (WT) isolates distribution and isolates with MIC values over
the ECOFF are considered non-wild type (NWT). The WT cluster in-
cludes isolates that are devoid of phenotypically detectable resistance
mechanisms, while NWT isolates are spread in a range of higher MIC
values as resistance mechanism are expressed. (Pfaller et al., 2011;
Kahlmeter, 2015). Visual inspection of MIC distribution is a common
method to determine the value of the ECOFF (Kahlmeter, 2014) and is
simpler than other methods involving statistics (Turnidge et al., 2006;
Kronvall, 2010). This study supported the visual assessment with a
statistical analysis using mixtures of one to four normal distributions
ﬁtted to the log-transformed MIC values by maximum likelihood, and
compared their support using Akaike’s Information Criterion (AIC) to
describe MIC distribution and identify ECOFF values. Final ECOFF va-
lues were conﬁrmed taking account recent literature including S. suis
ECOFF values (Callens et al., 2013), MIC distribution (de Jong et al.,
2014; van Hout et al., 2016) and the EUCAST antimicrobial resistance
database (http://mic.eucast.org)
Prevalence of WT and NWT for the diﬀerent antimicrobials and
subsets were compared using Pearson’s chi-square test, or Fisher’s exact
test for those tests with expected frequencies below 5.
2.3.2. Classiﬁcation using clinical breakpoints
Isolates were classiﬁed as sensitive, resistant or intermediate ac-
cording to the CLSI clinical breakpoints (2013b) for the Streptococcus
spp. for those antimicrobials with available recommendations: amox-
icillin/clavulanate (AMC), penicillin, ceftiofur, tetracycline, enro-
ﬂoxacin, trimethoprim/sulfamethoxazole (TMPS), erythromycin and
ﬂorfenicol. Diﬀerences in prevalence of resistant isolates within the
four subsets were assessed using the Pearson’s chi-squared test or
Fisher’s exact test when expected frequency values were below 5.
2.3.3. Diﬀerences in MIC values (including MIC50) between speciﬁc subsets
Changes in the characteristics of the MIC distributions for each
subset over time, or between CC and NCC subsets, were identiﬁed by
analysing each subset of MIC values for each antimicrobial with the
Mann-Whitney-Wilcoxon test. For bimodal and multimodal MIC dis-
tributions Mann-Whitney-Wilcoxon test and MIC50, calculated as the
median, were individually computed for WT and NWT clusters. MIC50
and the MIC90 were calculated as the MIC that inhibited the growth of
50 and 90%, respectively, of the isolates in a subset or cluster.
2.3.4. Number of NWT phenotypes per isolate for diﬀerent antimicrobial
classes
The 17 antimicrobials were classiﬁed into nine classes (Table 2). If
an isolate presented a NWT phenotype for an antimicrobial in the class,
it was considered as NWT for the whole class. Diﬀerences in prevalence
were assessed using the Pearson’s chi-squared test and Fisher’s exact
test as an alternative when computing expected values below 5.
Data were analysed with the statistical software R version 3.3.1 (R
Core team, Vienna, Austria) and SPSS (IBM Corp, Armonk, NY, USA). A
signiﬁcance level of 95% (p value of 0.05) was selected for all statistical
tests. Multiple analysis testing correction was not considered strictly
necessary in this study as it described ﬁndings from surveys without any
speciﬁc key hypothesis (Bender and Lange, 2001) consequently the
authors have designated these results as exploratory.
3. Results
Frequencies of MIC values for the diﬀerent antimicrobials were ta-
bulated separately for each of the four sample subsets and the combined
collection (Table 1, MIC values detailed for each subset on Supple-
mentary Table S1a–d), along with MIC50 values, MIC90 values and the
percentage of sensitive (S), intermediate (I) or resistant (R) isolates
where CLSI breakpoint values were available.
Table 1
MIC distribution for all S. suis isolates in the study between 2009 and 2014. (For interpretation of the references to colour in the Table, the reader is referred to the web version of this
article.)
 S. suis (n=405) 
Antimicrobial agent 
MIC values (µg/mL) MIC50 
(µg/mL) 
MIC90 
(µg/mL) 
S 
(%) 
I 
(%) 
R 
(%) 0.002 0.004 0.008 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 
Amoxicillin     382 14 3  3 1 1 1         0.03 0.03    
Amoxicillin/ 
Clavulanate*     381 14 3 1 3 1 1 1         
0.03 0.03 100% 0% 0% 
Penicillin     306 13 24 25 17 12 6 1         0.03 0.25 91% 4% 5% 
Cefquinome 5 2 51 168 114 49 8 5 3            0.015 0.06    
Ceftiofur     2 48 215 47 50 29 7 5 2        0.12 1 98% 1% 0% 
Doxycycline      15 59 5 2   8 122 181 12 1     8 16    
Tetracycline        2 9 26 38 6  3 86 202 26 7   64 64 3% 6% 91% 
Tiamulin      1 7 31 16 124 102 18 28 27 28 16 7    2 32    
Enrofloxacin       10 142 239 11 1 1  1       0.5 0.5 97% 3% 1% 
Marbofloxacin    20    6 151 216 11   1       1 1    
Trimethoprim/ 
Sulfamethoxazole**    26 83 97 23 47 43 18 21 18 9 10 2 8     
0.06 4 79% 10% 12% 
Tilmicosin         1 1 35 176 6 1 1 1  183   4 >128    
Tylosin        2 142 73 2 3     2 2 179  1 >256    
Erythromycin    47 149 21 2    4 8 7 1 3 163     0.06 >32 54% 0% 46% 
Lincomycin      4 29 19 24 63 32 12 25 5 2 2 31 157   8 >128    
Spectinomycin            8 84 235 53 1   1 23 16 32    
Florfenicol         1 82 311 11         2 2 97% 3% 0% 
Note: White cells indicate the dilution range tested. Values in the grey indicate MIC values over the highest concentration in the tested range. Green and red vertical lines respectively
describe the sensitive and resistant clinical breakpoints recommended by the CLSI (2013a,b). Detailed information about MIC values for each subset of isolates is available in the
supplementary tables.
*Amoxicillin/Clavulanate combination was tested in a concentration ratio of 2:1. MIC values in the table represent Amoxicillin concentrations.
**Trimethoprim/Sulfamethoxazole combination was tested in a concentration ratio of 1:2. MIC values in the table represent Sulfamethoxazole concentrations.
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3.1. MIC value distribution and ECOFF values
The MIC distribution patterns, ECOFF values and range of the dif-
ferent clusters for each antimicrobial are shown in Table 2. Unimodal
distributions were observed for ﬂorfenicol, ceftiofur and cefquinome
(Supplementary Fig. S1a–q). MIC distributions were multimodal in the
case of tetracycline, doxycycline, erythromycin, tilmicosin, tylosin,
lincomycin, tiamulin, spectinomycin and marboﬂoxacin. For TMPS a
complex distribution pattern was produced by apparent overlapping of
several phenotypic clusters. MIC distribution patterns for amoxicillin,
AMC, and penicillin were only partially characterized because more
than 75% of the isolates were susceptible to the minimum antimicrobial
dilution tested (0.003 μg/mL) (Supplementary Fig. S1a–c).
3.2. Diﬀerences in antimicrobial resistance between CC and NCC isolates
The percentage of isolates with a NWT phenotype was signiﬁcantly
higher in NCC than CC, in both 2009–2011 and 2013–2014 collections,
for penicillin, tiamulin, and TMPS (Table 3). However, this pattern was
not consistent for all antimicrobials, and CC isolates in 2013–14 pre-
sented a signiﬁcantly higher NWT prevalence than NCC in the
2013–2014 collection for spectinomycin, lincomycin, tylosin, ery-
thromycin and tilmicosin (Table 3). It is important to note, though, that
the comparison of CC and NCC isolates from 2013 to 2014 was based
upon an NCC collection obtained from a geographically restricted
subset of the original 2009–2011 NCC population source.
For those antimicrobials where a clinical breakpoint was available
(CLSI, 2013b), tetracycline resistant isolates were signiﬁcantly more
prevalent in NCC than CC in 2009–2011 and again in 2013–2014
(NCC = 97%, CC = 77%, P < 0.01; NCC = 100%, CC = 88%,
P < 0.01 respectively).
Signiﬁcant diﬀerences were observed in MIC values (including
MIC50) between CC and NCC subsets. In 2009–2011 MIC values were
higher among NCC than CC isolates for tetracycline (both NWT and WT
cluster), cefquinome and ceftiofur (Table 4). Higher values were also
seen for doxycycline (only in the NWT cluster) and erythromycin (only
in the WT cluster).
In 2013–2014 MIC values were signiﬁcantly higher for NCC isolates
than CC isolates for cefquinome and ceftiofur and in the WT cluster for
tetracycline, as noted in 2009–2011. MIC values were signiﬁcantly
higher for CC than NCC isolates in 2013–2014 for ﬂorfenicol, for the
NWT clusters of doxycycline, enroﬂoxacin, marboﬂoxacin and ery-
thromycin, and for the WT cluster of tiamulin.
3.3. Diﬀerences in antimicrobial resistance between 2009 and 2011 and
2013–2014
There was a trend towards increased resistance between the ﬁrst
(2009–2011) and second (2013–2014) period, in terms of NWT pre-
valence, prevalence of isolates over the CLSI clinical breakpoint and,
ﬁnally, MIC values for both NCC and CC subsets.
In CC isolates, NWT prevalence signiﬁcantly increased between
2009 and 2011 and 2013–2014 for marboﬂoxacin, tiamulin, TMPS and
spectinomycin (Table 3). For the NCC isolates, the NWT prevalence
signiﬁcantly increased between periods only for marboﬂoxacin.
Increases in prevalence of clinical resistance between the two time-
periods, based on CLSI breakpoints, were observed for tetracycline in
the CC subset (77% of isolates resistant in 2009–2011, 88% in
2013–2014; P < 0.05). Resistance prevalence was also higher in
2013–2014 compared to 2009–2011 for TMPS among CC isolates (6%
resistant in 2009–2011 versus 15% in 2013–2014; P < 0.05).
Diﬀerences in MIC values (including MIC50) between periods were
observed when comparing MIC values within equivalent clusters of
isolates based on their WT or NWT grouping (Table 5). This time-based
incremental change in resistance, termed as MIC creep, consisted of a
general shift of MIC values in a cluster between periods. It is graphically
represented as a slight movement of the MIC distribution towards
higher MIC values. MIC creep phenomena were more common in CC
isolates: doxycycline MIC50 values in the NWT cluster for CC were
higher in 2013–2014 compared to CC isolates in 2009–2011. For some
antibiotics, MIC distributions for CC isolates showed signiﬁcantly
higher values in 2013–2014 than 2009–2011 despite similar MIC50
values in both periods; This was found for cefquinome, ceftiofur, the
WT cluster for erythromycin, and the NWT cluster for tetracycline in CC
isolates.
For the NCC subsets, noting previously mentioned caveats over
comparability, MIC values were higher in 2009–2011 than 2013–2014
for NWT clusters of doxycycline and tetracycline (Table 5).
3.4. Combinations of increased resistance to multiple antimicrobials
Every isolate possessed a NWT phenotype for ﬂuoroquinolones and
Table 2
MIC distribution patterns, ECOFFs and range of the diﬀerent clusters in the whole data collection.
Class (subclass) Antimicrobial MIC distribution pattern ECOFF (μg/mL) Wild type cluster (μg/mL) Non wild type clusters (μg/mL)
Beta lactams
(Penams) Amoxicillin Unknown 0.12* ≤0.03–0.12 0.5–4
AMC Unknown 0.25* ≤0.03–0.25 0.5–4
Penicillin Unknown 0.03* ≤0.03 0.06–4
(Cephalosporins) Ceftiofur Unimodal NA 0.03–8 NA
Cefquinome Unimodal NA 0.002–0.5 NA
Amphenicols Florfenicol Unimodal NA 0.5–4 NA
Pleuromutilins Tiamulin Multi-modal 2 0.06 –>2 4 –>64
Tetracyclines Tetracycline Multi-modal 4 0.25–4 16 –>128
Doxycycline Multi-modal 0.5 0.06–0.5 4–64
Erythromycin Multi-modal 0.12 0.015–0.12 2 –>32
Macrolides Tylosin Multi-modal 4 0.25–4 128 –>256
Tilmicosin Multi-modal 32 0.5–32 >128
Lincosamides Lincomycin Multi-modal 0.25* 0.06–0.25 0.5 –>128
Aminocyclitol Spectinomycin Multi-modal 64 4–64 ≥512
Fluoroquinolones Enroﬂoxacin Multi-modal NA NA 0.12–4 and>8
Marboﬂoxacin Multi-modal 0.015 0.015 0.25–2 and 16
Potentiated sulphonamides TMPS Multi-modal 0.12* 0.015–0.12 0.25 –>32
Note: Antibiotics including ﬂorfenicol, ceftiofur and cefquinome presented a unimodal distribution therefore ECOFF values were not set and NWT cluster were not considered. Wild-type
cluster was not considered in the case of enroﬂoxacin.
AMC: Amoxicillin/Clavulanate. TMPS: Trimethoprim/Sulfamethoxazole. NA: Not applicable (ECOFF were unable to be deﬁned in this sample set).
*Tentative cut-oﬀ for the most susceptible cluster.
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a WT phenotype for amphenicols. Fourteen out of 405 isolates were
categorised as WT for all the antimicrobial classes excepting ﬂuor-
oquinolones. At least 56% of the isolates in every subset presented four
or more NWT phenotypes for the diﬀerent antimicrobial classes
(Table 6). NCC isolates accumulated a higher number of NWT pheno-
types than CC in both time periods reaching statistical signiﬁcance
when considering ﬁve or more NWT phenotypes per isolate
(P < 0.05). In general, the number of multiple NWT phenotypes per
isolate at class level was higher in 2013–2014 than 2009–2011. Pre-
valence of NWT for ﬁve or more classes in CC isolates was signiﬁcantly
higher in 2013–2014 than 2009–2011 (30% versus 16%; P < 0.05)
but no signiﬁcant diﬀerences were observed in NCC isolates between
periods. A small number of isolates (12/405) were identiﬁed as NWT
for all groups with the exception of cephalosporins and amphenicols,
and represented 2% of CC isolates in 2009–2011 and 8% of CC isolates
in 2013–2014 (Table 6).
A frequent combination of NWT phenotypes for CC isolates was
macrolides, tetracyclines, ﬂuoroquinolones and lincosamides, which
occurred in 48% of this collection (Supplementary Table S2).
4. Discussion
Despite the widespread and common involvement of S. suis in pig
and human disease around the world, a comprehensive set of inter-
nationally accepted clinical breakpoints for antimicrobial resistance
does not exist for this organism. Therefore, CLSI clinical breakpoints for
closely related organisms were considered in some cases but most of the
analysis was based upon the statistical comparisons of MIC value dis-
tributions between subsets of isolates, and the relative prevalence of
WT and NWT susceptibility phenotypes segregated by an ECOFF. While
Table 3
Non wild-type prevalence (%) for the diﬀerent antimicrobials depending on origin (clinical (CC) or non-clinical (NCC)) and the period of collection (2009–2011 or 2013–2014), with
indication of signiﬁcant diﬀerences between the groups when comparing the diﬀerent collections.
Prevalence per group (%) Pearson’s Chi-squared test*
2009/11 2013/14 2009/11 versus 2013/14 CC versus NCC
CC
n = 93
NCC
n = 66
CC
n = 117
NCC
n = 129
In CC In NCC In 2009/11 In 2013/14
Amoxicillin 1.1 3.0 0 2.3 ns ns ns ns
AMC 1.1 3.0 0 2.3 ns ns ns ns
Penicillin 9.8 34.8 14.5 38.0 ns ns P = 0.004 P = 0.0007
Cefquinome NA NA NA NA NA NA NA NA
Ceftiofur NA NA NA NA NA NA NA NA
Doxycycline 71.0 81.8 81.2 84.5 ns ns ns ns
Tetracycline 71.0 81.8 81.2 84.5 ns ns ns ns
Tiamulin 10.8 45.5 23.1 44.2 P = 0.020 ns P = 0.000001 P = 0.0005
Enroﬂoxacin 100 100 100 100 ns ns ns ns
Marboﬂoxacin 88.2 86.4 100 100 P = 0.0001 P = 0.00005 ns ns
TMPS 17.2 46.5 44.4 58.9 P = 0.00003 ns P = 0.00002 P = 0.023
Tilmicosin 45.2 36.4 54.7 41.1 ns ns ns P = 0.033
Tylosin 45.2 36.4 54.7 41.1 ns ns ns P = 0.033
Erythromycin 45.2 39.4 54.7 41.9 ns ns ns P = 0.044
Lincomycin 87.1 89.4 92.3 81.4 ns ns ns P = 0.012
Spectinomycin 3.2 3.0 13.7 2.3 P = 0.013 ns ns P = 0.001
Florfenicol NA NA NA NA NA NA NA NA
AMC: Amoxicillin/Clavulanate. TMPS: Trimethoprim/Sulfamethoxazole. NA: Not applicable due to the unimodal distribution of MIC values.
* ns: not signiﬁcant over P > 0.05. Fisher’s exact test was alternatively used when the frequency of expected values was under 5.
Table 4
Diﬀerences in MIC values (including MIC50, MIC90) between CC and NCC shown separately for 2009–2011 and 2013–2014.
Antimicrobial Cluster for 
comparison 
 
2009/11   
MIC50 ; MIC90 (µg/mL)  
2013/14   
MIC50 ; MIC90 (µg/mL)  
 CC NCC Sign.*  CC NCC Sign.* 
Cefquinome Unimodal  0.015 ; 0.03 0.015 ; 0.12 P=0.011  0.015 ; 0.03 0.03 ; 0.06 P=0.008
Ceftiofur Unimodal  0.12 ; 0.25 0.12 ; 1 P=0.001  0.12 ; 0.5 0.12 ; 1 P=0.00006 
Doxycycline NWT  8 ; 16 16 ; 16 P=0.001  16 ; 32 8 ; 16 P=0.0004 
Tetracycline WT  1 ; 2 2 ; 4 P=0.0018  1 ; 2 2 ; 4 P=0.0001 
Tetracycline NWT  64 ; 64 64 ; 128 P=0.000004     
Enrofloxacin NWT      0.5 ; 0.5 0.5 ; 0.5 P=0.031 
Tiamulin WT      1 ; 2 1 ; 2 P=0.004 
Marbofloxacin NWT      1 ; 1 0.5 ; 1 P=0.004 
Erythromycin WT  0.03 ; 0.03 0.03 ; 0.06 P=0.046     
Erythromycin NWT      >32 ; >32 >32 ; >32 P=0.008
Florfenicol Unimodal      2 ;2 2 ;2 P=0.005 
Note: Only those antimicrobial clusters with signiﬁcant diﬀerences are represented. See supplementary table S1a-d for absent values.
*Signiﬁcance determined by Mann-Whitney-Wilcoxon method. In blank those antimicrobials without signiﬁcant diﬀerences. In grey those MIC values that were higher than compared
group.
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this approach has been used for other microbial species (Pfaller et al.,
2011), to our knowledge this is the ﬁrst application to porcine S. suis
isolates representing two separated time periods.
Taken together, the isolates in this study had MIC and ECOFF values
in line with previous studies from other regions (Aarestrup et al., 1998;
Callens et al., 2013; de Jong et al., 2014; Gurung et al., 2015; Zhang
et al., 2015; van Hout et al., 2016). Data gaps in this study, which may
lead to potential bias, were the lack of information on pig ages, po-
tential for clustering of diagnostic laboratory submissions as farm level,
and antimicrobial use. In addition, NCC samples collected in 2013-14
originated from a pig population smaller than the other subsets, and
that could be epidemiologically related.
4.1. Identiﬁcation of ECOFF values
ECOFFs derived using the mathematical model agreed with these
obtained by subjective visual inspection in most but not all cases.
Where several logarithmic steps separated the MIC values of the WT
and NWT clusters then ECOFFs could easily be identiﬁed by the visual
approach. However, the mathematical model was particularly useful in
identifying ECOFF values where there was overlap of the WT and NWT
clusters. Previously reported models barely improved visual inspection
ECOFF choices (Turnidge et al., 2006; Kronvall, 2010). Although the
model was designed to minimise the misclassiﬁcation of isolates either
side of the ECOFF biases likely exist and future models will beneﬁt from
the incorporation of genetic as well as phenotypic information. Such
further reﬁnement of mathematical methods for ECOFF identiﬁcation is
an important step towards standardisation of antimicrobial resistance
surveillance.
4.2. Non-disease associated (NCC) isolates showed increased antimicrobial
resistance compared to disease-associated (CC) isolates
Increased antimicrobial resistance was found for the NCC subsets
compared to the CC subsets. The same eﬀects were found for the
2009–2011 and the 2013–2014 subsets for NWT prevalence, prevalence
of resistance based on published clinical breakpoints and by compar-
ison of MIC values. Earlier studies of diﬀerential antimicrobial sus-
ceptibility among S. suis isolates from diseased or healthy pigs found no
diﬀerence or described an increased prevalence of the macrolide-lin-
comycin-streptogramin B resistance phenotype (MLSB) among isolates
from healthy sows versus isolates from diseased slaughter pigs (Zhang
et al., 2015). More recently diﬀerent resistance proﬁles for isolates from
healthy or diseased slaughter pigs in Korea were described but statis-
tically signiﬁcant diﬀerences were not reported (Gurung et al., 2015).
Correlations between serotype, as a proxy for disease association,
and antimicrobial resistance have previously been reported (Aarestrup
et al., 1998; Wisselink et al., 2006) however those comparisons only
considered serotyped disease-associated isolates. More recently,
genome-wide association studies of large populations of disease-asso-
ciated and non-disease associated S. suis revealed enormous diversity
and recombination among isolates, and highlighted a signiﬁcantly
smaller genome size for disease-associated isolates (Weinert et al.,
2015) and very low prevalence of disease-associated genomotypes of S.
suis in the upper respiratory tract of healthy pigs. Evidence from other
microbial contexts indicates that antimicrobial resistance, while con-
ferring selective protection, can carry a broader biological cost
(Andersson, 2006) that might impact on competitive ﬁtness in ecolo-
gical niches such as the upper respiratory tract. Ongoing investigation
of the genomic basis for observed antimicrobial resistance phenotypes
in this current collection will shed new light on the potential role of
Table 5
Diﬀerences in MIC values (including MIC50, MIC90) between 2009 and 2011 and 2013–2014 collections shown separately for CC and NCC groups.
Antimicrobial Cluster for 
comparison
CC   
MIC50 ; MIC90 (µg/mL)
NCC   
MIC50 ; MIC90 (µg/mL)
2009/11 2013/14 Sign.* 2009/11 2013/14 Sign.*
Cefquinome Unimodal 0.015 ; 0.03 0.015 ; 0.03 P=0.003
Ceftiofur Unimodal 0.12 ; 0.25 0.12 ; 0.5 P=0.040
Doxycycline NWT 8 ; 16 16 ; 32 P=0.00003 16 ; 16 8 ; 16 P=0.002
Tetracycline NWT 64 ; 64 64 ; 64 P=0.00003 64 ; 128 64 ; 128 P=0.014
Erythromycin WT 0.03 ;  0.03 0.03 ; 0.06 P=0.001
Note: Only represented those antimicrobial clusters with signiﬁcant diﬀerences. See supplementary table S1a-d for absent values.
*Signiﬁcance. p-values calculated by Mann-Whitney-Wilcoxon method. In blank those antimicrobials without signiﬁcant diﬀerences. In grey those MIC values that were higher than
compared group.
Table 6
Cumulative frequency of isolates (as%) showing NWT phenotypes for multiple antimicrobial classes.
Number of NWT phenotype for
diﬀerent antimicrobial groups.
2009/11 2013/14 2009/11 vs 2013/14 CC vs NCC
CC
n = 93
NCC
n = 66
CC
n = 117
NCC
n = 129
in
CC
in
NCC
in
2009/11
in
2013/14
≥1 100% 100% 100% 100% ns ns ns ns
≥2 98% 95% 99% 94% ns ns ns ns
≥3 63% 88% 85% 81% P= 0.0004 ns P = 0.0006 ns
≥4 56% 67% 66% 77% ns ns ns ns
≥5 16% 41% 30% 45% P= 0.020 ns P = 0.0005 P = 0.015
≥6 6% 30% 21% 32% P= 0.004 ns P = 0.00006 P = 0.007
≥7 4% 15% 15% 20% P= 0.009 ns P = 0.017 ns
8 2% 2% 8% 0% ns ns ns P = 0.001
Note: ten groups of antimicrobials were considered beta-lactams (penams and cephalosporins), macrolides, lincosamides, tetracyclines, aminoglycosides, pleuromutilins, amphenicols,
ﬂuoroquinolones and the combination of Trimethoprim/Sulfamethoxazole. Statistics performed with Pearson’s chi-squared test or Fisher’s exact test when expected frequency were lower
than 5.
ns: no signiﬁcant diﬀerence (p > 0.05).
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non-disease associated isolates as reservoirs for horizontally transmis-
sible antimicrobial resistance genes. It should also be noted that isolates
categorised as non-clinical in this study might, under conditions of re-
duced immunity, be able to escape from the upper respiratory tract to
cause systemic disease. However, at the level of clinical veterinary
practice and national surveillance for trends in antimicrobial resistance,
this ﬁnding emphasises the importance of considering the clinical his-
tory of isolates when interpreting antimicrobial susceptibility test data.
4.3. Antimicrobial resistance increased in S. suis between both periods
The data showed a general trend of higher resistance between 2009
and 2011 and 2013–2014, in agreement with previous European studies
of S. suis antimicrobial resistance conducted over recent years (Varela
et al., 2013; van Hout et al., 2016). The change was particularly ap-
parent among CC isolates for tiamulin, marboﬂoxacin, TMPS, specti-
nomycin, tetracyclines, cephalosporins and macrolides. All of these
antimicrobials were used in the English pig industry before the samples
used in this study were collected.
Voluntary prescribing guidance published by the UK’s Pig
Veterinary Society places ﬂuoroquinolones and 3rd or 4th generation
cephalosporins (ceftiofur and cefquinome) in a category of anti-
microbials intended for use only as a last resort and supported by la-
boratory sensitivity tests. The prevalence of NWT phenotype for mar-
boﬂoxacin among CC and NCC isolates increased to 100% between
2009 and 2011 and 2013–2014. Isolates which were WT for marbo-
ﬂoxacin in 2009–2011 were found to have a NWT phenotype for en-
roﬂoxacin, another ﬂuoroquinolone. A decrease in ﬂuoroquinolone
susceptibility in S. suis and S. pneumoniae has been described as a
stepwise process in which ﬁrst-step mutations had a preferential target
in genes encoding elements of topoisomerase IV (parC, parE) or DNA
gyrase (gyrA) for a reduced number of ﬂuoroquinolones. In a second
step, more amino acid substitutions are accumulated, also aﬀecting
repression of an ABC transporter eﬄux pump so resistance is sig-
niﬁcantly increased, conferring resistance to additional ﬂuoroquinolone
types (Escudero et al., 2011). Therefore, surveillance programs that
monitor for low-level resistance against more than one ﬂuoroquinolone
have merit in detecting early and low, but progressive, resistance in-
crease against this important class of antimicrobials.
Statistically signiﬁcant but subtle increases in resistance were found
for ceftiofur and cefquinome between the ﬁrst and second time-periods.
Comparison of MIC values showed an overall increase, or creep, be-
tween periods for both antimicrobials; although only a marginal change
in MIC50 was found there was a shift in overall MIC distributions. The
prevalence of resistant isolates according to the CLSI breakpoint for
ceftiofur showed no signiﬁcant change between 2009 and 2011 and
2013–2014 highlighting the potential limitations of surveillance based
on clinical breakpoints for monitoring antimicrobial susceptibility
trends.
Beta lactam antimicrobials other than cephalosporins, and espe-
cially penams, are considered as a ﬁrst option in the UK to treat S. suis-
related diseases. Indeed, penicillin-resistant isolates have been in-
creasingly detected in recent years among pig isolates from European
and Asian countries (Zhang et al., 2008; Callens et al., 2013). In this
study, there was no evidence of any statistically signiﬁcant change in
resistance to penicillin, amoxicillin or amoxicillin/clavulanate. This
ﬁnding concurs with those of routine surveillance reported by APHA,
which describes a small number of penicillin-resistant clinical and non-
clinical S. suis isolates since 2009 with no evidence of an increasing
trend in penicillin MICs undertaken periodically on disease-associated
S. suis isolates (APHA, 2015).
4.4. Combinations of increased resistance to multiple antimicrobials have
become more prevalent and complex between periods
The carriage by S. suis of multiple resistance determinants is already
well described (Chen et al., 2013) but the ﬁnding of increased pre-
valence and diversity of this phenomenon between both periods and
also between subsets of non-disease associated NCC versus disease-as-
sociated CC origin was novel. Although the clinical implications for
these resistances may not yet be fully apparent in veterinary practice as
clinical breakpoints may not yet have been exceeded, there was a clear
indication of ongoing and progressively increasing resistance for mul-
tiple antimicrobials. These ﬁndings, when combined with genomic
data, may enable a better understanding of the co-selection of re-
sistance and the impact of selective advantages and broader biological
costs of antimicrobial resistance mechanisms on bacterial ﬁtness and
disease association.
Surveillance of antimicrobial resistance for endemic, and especially
zoonotic, veterinary pathogens such as S. suis using internationally
standardised methods is likely to become the focus of ever-increasing
attention as steps are taken to develop more rational evidence-based
approaches to antimicrobial use in food animal production. From the
perspective of clinical veterinary management of disease, MIC value
distributions and epidemiological cut-oﬀs are less helpful in predicting
clinical success of antibiotic treatments compared to clinical break-
points− where such breakpoints are available. However, the power of
surveillance based on MIC values and NWT prevalence lies in their
prospective usefulness in early identiﬁcation of changes in S. suis an-
timicrobial susceptibility and the emergence of resistant strains, as well
as for monitoring the eﬀectiveness of antimicrobial resistance control
strategies. Such changes may be detected before the practical con-
sequences of antimicrobial resistance, based on clinical breakpoint
data, become apparent.
5. Conclusion
Large-scale studies of the antimicrobial resistance phenotype of
bacterial isolates are necessary to assign ECOFF values and clinical
veterinary breakpoints. This study used standardised methods and
carefully curated groups of isolates to identify signiﬁcant shifts in an-
timicrobial resistance phenotypes of S. suis, isolated from pigs in
England, not only between two time periods but also between isolates
with known disease or non-disease associated background. Nonetheless,
we highlighted relevant data gaps and potential biases in our sample set
which reﬂect the challenge of composing suﬃciently large collections,
with detailed phenotypic data, for statistically meaningful analysis of
this important zoonotic pig pathogen.
Surveys such as this represent a prerequisite step to better under-
standing of the connections between genotype, phenotype and clinical
antimicrobial responses. Outputs from such surveys, when combined
with subsequent genome sequencing, represent a crucial step towards
comprehensive understanding of the genomic basis for the biology,
evolution and management of antimicrobial resistance. Such combined
approaches are likely to be valuable in optimising antimicrobial re-
sistance surveillance programs, informing appropriate clinical anti-
microbial usage, and ensuring future availability of eﬀective anti-
microbials.
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